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Abstract
Background: Costing studies are useful to measure the economic burden of cancer. Comparing 
costs between healthcare systems can inform evaluation, development or modification 
of cancer care policies.
Objectives: To estimate and compare cancer costs in British Columbia and Ontario from 
the payers’ perspectives.
Methods: Using linked cancer registry and administrative data, and standardized costing 
methodology and analyses, we estimated costs for 21 cancer sites by phase of care to determine 
potential differences between provinces. 
Results: Overall, costs were higher in Ontario. Costs were highest in the initial post-diagnosis and 
pre-death phases and lowest in the pre-diagnosis and continuing phases, and generally higher for 
brain cancer and multiple myeloma, and lower for melanoma. Hospitalization was the major cost 
category. Costs for physician services and diagnostic tests differed the most between provinces.
Conclusions: The standardization of data and costing methodology is challenging, but it enables 
interprovincial and international comparative costing analyses.
Résumé
Contexte : Les études de coûts sont utiles pour mesurer le fardeau économique du cancer. La 
comparaison des coûts entre systèmes de santé peut éclairer l’évaluation, l’élaboration ou la 
modification des politiques pour les soins contre le cancer.
Objectif : Estimer et comparer les coûts pour les soins contre le cancer en Colombie-
Britannique et en Ontario du point de vue des payeurs.
Méthode : Au moyen d’un registre sur le cancer et de données administratives liées, et au 
moyen d’analyses et d’une méthodologie des coûts normalisés, nous avons estimé le coût de 
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21 sièges du cancer selon les étapes de soins afin de dégager les différences entre les provinces. 
Résultats : Dans l’ensemble, les coûts sont plus élevés en Ontario. Les coûts étaient plus élevés pour les 
étapes initiales de post-diagnostic et de pré-mortalité et ils étaient plus bas pour les étapes de pré-diag-
nostic et de continuité, et généralement plus élevés pour le cancer du cerveau et le myélome multiple, 
mais moindre pour le mélanome. L’hospitalisation constitue la principale catégorie de coût. Les coûts 
pour les services de médecins et les tests diagnostics sont ceux qui varient le plus entre les provinces.
Conclusion : La standardisation des données et des méthodologies pour les coûts présente 
un défi, mais elle permet d’effectuer des analyses comparatives des coûts interprovinciales 
et internationales.
T
Introduction
Cancer-related healthcare costs are rising in Canada (CIHI 2011). The most recent estimate 
of the total cost of cancer care in Canada is $4.4 billion for 2008 (PHAC 2014). Given limited 
financial resources, funders of cancer care struggle to provide patients with the best therapies. 
Descriptive costing studies reflect the burden to healthcare systems and help translate the 
effects of health conditions into dollars. Furthermore, comparative studies between healthcare 
systems can inform evaluation, development or modification of policies and programs related 
to cancer screening, treatment and delivery of care (Lipscomb et al. 2013). For example, a 
study comparing resource use for end-of-life care in patients with lung cancer in Ontario and 
Surveillance, Epidemiology and End Results (SEER) regions in the US found that hospi-
tal and emergency room services were used more extensively among Ontario patients, while 
chemotherapy use was significantly higher among SEER-Medicare patients (Warren et al. 
2011). Ontario palliative care was more likely to be administered in the hospital, whereas more 
home and hospice care was used by SEER-Medicare patients. Such findings could have impor-
tant policy implications for both countries regarding current end-of-life care patterns, and may 
identify opportunities for changing practice patterns or programs.
Differences in healthcare delivery, costs and populations across Canada suggest that compara-
tive interprovincial studies could improve cancer care; however, no previous work has undertaken 
comparative cost analyses between Canadian provinces. Thus far, work has been done in indi-
vidual provinces, such as British Columbia (BC) (Pataky et al. 2016), Alberta (Fassbender et al. 
2009) and Ontario (Krahn et al. 2010; Mittmann et al. 2012, 2014), examining utilization and 
costs for individual cancer sites and/or single phases of care. One study has estimated costs for 
various cancer sites in Ontario, but only for the first year after diagnosis (de Oliveira et al. 2013a).
The objectives of this study were to estimate and compare the direct costs for the 21 most 
common cancer sites, from diagnosis to death, in two large Canadian provinces with similar 
data holdings, BC and Ontario, from payers’ perspectives (the respective Ministries of Health), 
and to examine potential differences in costs and their drivers. The resulting estimates, 
based on high-quality evidence, will aid decision-makers on issues, such as efficiency/system 
Estimating the Cost of Cancer Care in British Columbia and Ontario
e[98] HEALTHCARE POLICY Vol.12 No.3, 2017
performance and resource allocation. Despite challenges associated with harmonizing cost-
ing methodology and analyses between Canadian provinces, such standardization will enable 
comparisons at provincial, national and international levels.
Methods
Patients
We selected all patients diagnosed with cancer who were 19 years and older from January 1, 
1997, to December 31, 2007, from each provincial cancer registry (BCCA 2010; Hall et al. 
2006) based on available data. We included patients with a primary cancer assigned a single, 
valid International Classification of Diseases for Oncology topography code with a valid his-
tology code (brain, female breast, cervix, colorectal, corpus uteri, esophagus, gastric, head and 
neck, leukemia, liver, lung, lymphoma, melanoma, multiple myeloma, ovary, pancreas, pros-
tate, renal, testis, thyroid, urinary bladder and a category combining all other tumour sites) 
(Appendix 1; available at: http://www.longwoods.com/content/25024). We excluded patients 
with a date of cancer diagnosis that coincided with date of death, not residing in the province 
of  diagnosis, or who did not have a valid provincial health insurance number. 
Data 
Data for chemotherapy and radiation therapy (RT) were obtained from the BC Cancer Agency 
(BCCA) and Cancer Care Ontario. Data on other health services were obtained through 
Population Data BC in BC, and the Institute for Clinical Evaluative Sciences (ICES) in Ontario 
(Table 2 in Appendix 1). These data were linked to the respective cancer registry data using 
patient-unique provincial health plan numbers. Population Data BC and ICES follow prac-
tices to protect the privacy and confidentiality of individuals and information. The study was 
approved by the BC Cancer Agency; the Institutional Review Board at Sunnybrook Health 
Sciences Centre, Toronto, Canada; and the University of Toronto Research Ethics Boards.
Valuing health resources
Measuring healthcare costs generally requires two components: utilization of data (i.e., quan-
tity of resources) and unit cost data (i.e., cost of resources). This information was collected 
for chemotherapy, RT, in-patient hospitalizations, same-day surgery/procedures, physician 
services, diagnostic tests, out-patient prescription drugs and home and community care. Total 
cost estimates for in-patient hospitalizations and same-day surgery/procedures were obtained 
by multiplying the resource intensity weight (measure of resource utilization intensity) by the 
cost per weighted case (unit cost) (Baladi 1996; CIHI 1995; Pink and Bolley 1994; Wodchis et 
al. 2011). Cost estimates for other resources were available in the data or obtained from other 
sources (Earle et al. 1999; Wodchis et al. 2011). These costing methods follow the guidelines of 
the Canadian Agency for Drugs and Technologies in Health (CADTH 2006) and are based on 
previous cancer costing work in Ontario (de Oliveira et al. 2013a; Krahn et al. 2010). Healthcare 
costs included the costs of cancer care and the costs of caring for other health problems.
Claire de Oliveira et al.
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Harmonization
Because of privacy legislation, data were analyzed separately in each province; this limited 
our ability to undertake aggregate analyses. Nonetheless, we tried to define and measure all 
pertinent variables in the same manner. Some challenges are described below.
Date of diagnosis
The cancer registries defined diagnosis date differently. BC legally mandates the reporting of 
cancer (active registration); diagnosis is based on the date of cytological or histological diag-
nosis. Ontario has passive registration where ascertainment of diagnosis date relies on various 
administrative records. Date of diagnosis is the earliest date of hospital admission with a 
cancer diagnostic code, biopsy, visit to a cancer centre or death (if cause of death is cancer). 
To address this difference, the diagnosis date for BC patients diagnosed in the hospital was 
recoded as the date of hospital admission. 
Cost of chemotherapy
In Ontario, all chemotherapy is delivered at provincial cancer centres. The provincially 
funded New Drug Funding Program and the Ontario Drug Benefit (ODB) Program also 
provide chemotherapy drugs; this required a careful survey of the data to capture chemo-
therapy accurately. BCCA’s Provincial Systemic Therapy Program funds chemotherapy; 
drug costs are available from program data. Appointment records for chemotherapy deliv-
ery outside BCCA regional cancer centres were not available; hence, a mean chemotherapy 
delivery cost was assigned to unique patient-days from the Systemic Therapy Program 
dispensing records.
Cost of RT
Ontario uses the National Hospital Productivity Improvement Program codes to measure 
RT resource intensity, whereas BC does not; this made direct utilization comparison cum-
bersome. Furthermore, RT costs could not be obtained from the BC data; thus, we applied 
the Ontario cost per fraction estimate (Earle et al. 1999) to BC utilization data.
Cost of physician services
Canadian physicians are paid in several ways – fee-for-service, salary, capitation, alternate 
funding arrangements and combinations of these. The Ontario Health Insurance Plan 
(OHIP) claims database includes fee-for-service payments and shadow billings (that is, a way 
to track services provided by physicians who are not paid fee-for-service). However, the BC 
Medical Services Plan (MSP) data only include fee-for-service billings (BC MOH 2012b). 
BC oncologists are paid through alternative funding arrangements with the BCCA, so we 
used the BCCA appointment records and unit costs from the MSP fee schedule to assign 
costs to oncologist visits. We also assigned “treatment planning” costs to radiation oncologist 
visits, derived from the OHIP fee schedule, based on the complexity of the RT delivered. 
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Cost of diagnostic tests
The cost of diagnostic tests, including the professional and technical components, was obtained 
from the MSP and OHIP databases for BC and Ontario, respectively, with a few exceptions. 
For example, the costs of histology and specialized cancer-specific diagnostic tests were not 
included in the MSP (they are covered by other provincial budgets). We were unable to capture 
all costs through alternative data sources; thus, we underestimated the true cost in BC.
Cost of out-patient prescription drugs
In Canada, out-patient prescription drugs are covered under public and private insurance 
plans, or paid out-of-pocket. In BC, PharmaNet provides data on all out-patient prescription 
drugs, including those covered by BC PharmaCare (publicly paid plan) (BC MOH 2012c). 
This plan was age-based until 2002 and then became income-based (Morgan et al. 2006). In 
Ontario, only data on out-patient drugs paid by the publicly paid ODB program, which cov-
ers individuals aged 65 years and older and special cases (MOHLTC 2014), were available, 
which limited our ability to account for all drug-related costs. Thus, to ensure comparability 
between provinces, we included publicly paid prescription drugs in BC only. The samples of 
patients covered under the publicly paid plans in each province were quite similar. 
Cost of home and community care
Home and community care is organized under different names in each province. In particu-
lar, in BC, complex continuing care is not defined in the same manner as in Ontario (and 
thus could not be compared individually), but is provided under home and community care 
(in Ontario, this is defined as other institution-based care for people who have long-term ill-
nesses or disabilities typically requiring skilled, technology-based care not available at home 
or in long-term care facilities) (BC MOH 2012a). To overcome differences in the structure 
of home and community care data, and ensure the inclusion of comparable services, we 
aggregated all home and community care, including complex continuing care, long-term care, 
home nursing and home support, into one category within each province. Data on home and 
community care were missing for two health authorities in BC in later years of observation, 
so these values were imputed.
Cost of other care
Finally, few facilities in BC reported data on emergency department visits and/or other 
ambulatory care to the National Ambulatory Care Reporting System during the analy-
sis period; given the availability of limited data (which would not enable an accurate 
comparison), we excluded this type of care from our analysis. 
Estimating healthcare costs over time: phase of care approach
We used a phase-based approach (Baker et al. 1991; Brown et al. 1999; Yabroff et al. 2008) 
to estimate the costs incurred before and after diagnosis, and to deal with patients who 
Claire de Oliveira et al.
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entered and exited or were censored from the study cohort at different times. All patients 
had a pre-diagnosis phase, defined as the three months before the date of diagnosis. This 
phase typically includes diagnostic testing to establish the cancer diagnosis (Christensen et 
al. 2012; Hornbrook et al. 2013). We divided the time between diagnosis and death into the 
following three phases based on clinical relevance and join point analysis (Baker et al. 1991; 
Kim et al. 2000; Yabroff et al. 2008): (1) initial care, which includes the primary course 
of therapy and any adjuvant therapy, defined as the six months after diagnosis (including 
date of diagnosis); (2) continuing care, which encompasses surveillance and active follow-up 
treatment for cancer recurrence and/or new primary cancer, with costs expressed as annual 
estimates; and (3) terminal care, which captures intensive services, often palliative in nature, 
defined as the 12 months before death. Patients who died had their time first assigned to 
the terminal phase; their remaining time, and all time of patients who survived, was then 
assigned to the initial phase and then the continuing phase (Brown et al. 1999; Yabroff et al. 
2008). Patients with cancer who died of any cause during the analysis period were included.
We estimated mean costs for each cancer by phase of care and respective 95% confidence 
intervals. We also examined costs by resource (as defined above) for the four most common 
cancers (breast, colorectal, lung and prostate) for the initial and terminal phases to under-
stand the cost drivers, and to enable detailed interprovincial comparisons of cost components. 
(Costs by resource for all cancers are available upon request.) Costs were adjusted to 2009 
Canadian dollars (Statistics Canada 2014).
Results
Patients’ characteristics
Table 1 describes patients’ characteristics in Ontario (N = 402,399) and BC (N = 150,971). 
The proportions of patients by cancer site were approximately the same in both provinces, 
except for prostate, lung, breast, colorectal, thyroid (in line with previous findings; Thyroid 
Cancer Canada 2014) and lymphoma. Patients’ mean age was 65 years; approximately 52% 
were male. Slightly more patients were in the two lower-income quintiles in BC; the opposite 
held for Ontario. In both provinces, 85% of patients lived in urban settings and about 1% 
lived in long-term care facilities at time of diagnosis.
Mean costs by phase of care
Mean total costs across phases were generally higher in Ontario than in BC, with greater 
variation in costs across cancers for Ontario. For most cancer sites and phases of care, confi-
dence intervals for costs for each province did not overlap, suggesting significant differences. 
Nonetheless, the ranking of costs by cancer was generally the same at the tail ends of the dis-
tributions in both provinces. For the pre-diagnosis phase, costs varied from $733 to $3,833 in 
BC and $1,016 to around $4,660 in Ontario (Table 2, available at: http://www.longwoods.
com/content/25024). In both provinces, costs were highest for brain and bladder, and lowest 
for renal and thyroid cancers. All patients contributed to this phase.
Estimating the Cost of Cancer Care in British Columbia and Ontario
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TABLE 1. Patients’ characteristics
Characteristic British Columbia, N (%) Ontario, N (%)
Total 150,971	 402,399	
Cancer site
Prostate 27,828	(18.4) 68,940	(17.1)
Breast 23,965	(15.9) 68,709	(17.1)
Colorectal 19,033	(12.6) 58,659	(14.6)
Lung 18,383	(12.2) 42,046	(10.4)
Melanoma 5,953	(3.9) 17,059	(4.2)
Bladder 3,561	(2.4) 12,580	(3.1)
Head and neck 4,307	(2.9) 12,462	(3.1)
Corpus uteri 4,126	(2.7) 12,352	(3.1)
Thyroid 2,058	(1.4) 11,448	(2.8)
Lymphoma 7,487	(5.0) 10,467	(2.6)
Renal 3,155	(2.1) 10,204	(2.5)
Gastric 2,757	(1.8) 8,107	(2.0)
Leukemia 3,781	(2.5) 8,052	(2.0)
Ovary 2,246	(1.5) 7,167	(1.8)
Pancreas 3,044	(2.0) 6,358	(1.6)
Brain 2,115	(1.4) 5,462	(1.4)
Cervix 1,571	(1.0) 4,819	(1.2)
Esophagus 1,667	(1.1) 4,349	(1.1)
Myeloma 1,812	(1.2) 4,315	(1.1)
Testis 1,044	(0.7) 3,054	(0.8)
Liver 1,310	(0.9) 2,640	(0.7)
Other tumours 9,768	(6.5) 23,150	(5.8)
Age at diagnosis
Mean (SD) 65.0	(14.00) 63.5	(13.95)
Median (IQR) 66	(56-75) 65	(54-74)
Sex
Female 71,599	(47.4) 196,017	(48.7)
Male 79,372	(52.6) 206,382	(51.3)
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Costs increased greatly in the initial phase of care (Table 2). These varied from just 
over $3,000 to $32,376 in BC and from $5,250 to $43,409 in Ontario. Costs were highest 
for cancers with poor survival rates, such as brain, esophageal, pancreatic and gastric can-
cers, and lowest for those with high survival rates, such as melanoma, thyroid and prostate 
cancers. Approximately 82% of patients contributed to this phase.
Costs in the continuing phase varied from $1,978 and $2,858 to around $16,992 and 
$19,340 for BC and Ontario, respectively (Table 2). Mean total continuing care costs were 
highest for multiple myeloma and lowest for melanoma, thyroid, cervical and testicular 
cancers. Approximately 77% of patients were included in this phase.
Mean costs were highest for the terminal phase of care and varied from about $33,632 to 
$75,950 in BC and $39,645 to $89,544 in Ontario (Table 2). Costs were higher for brain cancer 
and lower for melanoma. The high costs for testicular cancer, $75,911 and $74,558 in BC and 
Ontario, respectively, were mainly driven by a small group of older males. Approximately 45% of 
our patient sample died before the end of our observation period and thus contributed to this phase.
Mean costs for the initial and terminal phases by resource for the four common cancers 
In both the initial and terminal phases, in-patient hospitalizations represented the highest costs 
for all cancers (Figure 1). In the initial phase, we found small interprovincial differences in the 
costs for some resources, such as same day-surgery and RT. For example, lung cancer costs with 
same-day surgery were virtually identical in BC ($601) and Ontario ($635). We found large 
cost differences for chemotherapy, especially for prostate cancer, largely owing to the inclu-
sion of hormone therapy under systemic therapy in BC ($1,024 in BC versus $18 in Ontario), 
Characteristic British Columbia, N (%) Ontario, N (%)
Neighbourhood income quintile
Missing 1,563	(1.0) 1,683	(0.4)
1	–	Low 32,199	(21.3) 75,662	(18.8)
2	–	Medium–low 29,648	(19.6) 81,882	(20.3)
3	–	Medium 28,877	(19.1) 79,363	(19.7)
4	–	Medium–high 28,917	(19.2) 79,577	(19.8)
5	–	High 29,767	(19.7) 84,232	(20.9)
Urban/rural residence 
Missing 130 (0.1) 0 (0.0)
Urban 127,934	(84.7) 342,751	(85.2)
Rural 22,907	(15.2) 59,648	(14.8)
Residence in long-term care facility 1,953	(1.3) 3,871	(1.0)
IQR = interquartile range; SD = standard deviation.
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physician services and diagnostic tests. Cost estimates for physician services were systematically 
higher in BC than in Ontario for all cancer sites, while the opposite held for diagnostic tests.
In the terminal phase, we found small interprovincial differences in the costs for 
same-day surgery, RT and, in some cancers, home and community care and in-patient hos-
pitalizations (Figure 2). For example, for same-day surgery, the cost difference between 
provinces was less than $30 for any given cancer. The cost differences for out-patient pre-
scription drugs, diagnostic tests and physician services were large. In particular, we found the 
same cost pattern for the latter two resources similar to that in the initial phase of care.
Discussion
In both provinces, and across cancers, costs were highest in the terminal phase, followed by the initial 
phase. On average, costs were highest among cancers with poor survival rates, such as brain cancer, 
and lowest for melanoma, with better survival. Our ranking of costs is in line with other work from 
Claire de Oliveira et al.
FIGURE 1.	Mean	costs	(2009	Canadian	dollars)	for	the	initial	phase	of	care	by	resource	for	the	four	
most common cancers in BC and ON
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FIGURE 2.	Mean	costs	(2009	Canadian	dollars)	for	the	terminal	phase	by	resource	for	the	four	most	common	
cancers in BC and ON
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Ontario (de Oliveira et al. 2013a; Krahn et al. 2010) and the US (Yabroff et al. 2008). Previous 
research also found that (net) costs in the initial and terminal phases of care in the SEER-Medicare 
population were highest for brain cancer and lowest for melanoma (Yabroff et al. 2008). 
Cancer-related treatment protocols are expected to be similar across Canada; yet, costs 
were generally higher in Ontario than in BC. Most cost differences are likely due to dif-
ficulties in harmonizing costing methods, missing data and the need to impute data. Some 
interprovincial cost differences were specific to a resource category. For most cancers, hos-
pitalization costs were higher in Ontario owing to unit cost estimates (i.e., higher cost per 
weighted case values). Lower costs for diagnostic tests in BC were owing to the fact that some 
tests are not included in the MSP. Over our analysis period, there were many changes in 
Ontario with the introduction of alternative payment plans that affected the way physicians 
reported services rendered to patients. These may not be fully captured in the administrative 
data. Thus, we speculate that lower costs for physician services in Ontario may be because of 
an underestimation of service use through shadow billings, for example. Furthermore, differ-
ences between provinces are likely a reflection of differences in the organization and coverage 
of services provided, such as home and community care, and the generosity of coverage of 
out-patient prescription drugs under each public healthcare plan. 
The findings from this study may help decision-makers on issues around health system 
efficiency and system performance. In particular, these results can provide insight on issues 
such as resource allocation (within and across cancer sites) and planning of future provin-
cial healthcare budgets. In addition, this work may provide some understanding of system 
efficiency/performance, namely, on how provinces can learn from one another regarding suc-
cessful cost-containment strategies and improvements around quality of care.
Undertaking cross-national or within-country costing studies can be challenging because 
administrative data, medical records and cancer registries were not designed for this type of 
research (Lipscomb et al. 2013). Differences in the organization of healthcare systems (cover-
age policies, payment of physicians and submission of claims) can make cost comparisons quite 
complex (Lipscomb et al. 2013). Even within Canada, comparison of cancer-specific care, such 
as chemotherapy and RT, requires care because data are not recorded in a standard manner 
across provinces, and cost estimates are rarely available in the data. Comparison of hospitali-
zation costs presents fewer challenges, as standard data are reported in the same database 
across Canada, except for Quebec. However, despite the standard data structure, differences 
in coding versions (CIHI 2009) and cost per weighted case estimates over time can introduce 
bias between jurisdictions. This is particularly important, as hospitalizations represent a large 
portion of the total cost. Attention may also be required to appropriately capture costs for 
physician services (fee-for-service versus alternative payment plans) and diagnostic tests (physi-
cian and technician billings versus global budgets), and ensure that resource categories include 
the same type of care (for example, home and community care). Yet, the standardization of 
the costing methods among provinces will enable researchers to obtain accurate cost estimates 
at the national level and can aid in making international comparisons. This is one of the first 
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studies to undertake this type of comparative analysis; while some limitations exist, this work 
has provided relevant insights. Future work should focus on developing and furthering the 
harmonization of costing methods between provinces.
Our study used rich administrative healthcare data and included large population-based 
samples of adults over the age of 18 years in BC and Ontario. We included cancers, such as mul-
tiple myeloma and those typically diagnosed among younger adults, such as thyroid and testicular 
cancers, which have not been examined previously, particularly in studies from the US examining 
Medicare data (patients aged 65 years and older) (Yabroff et al. 2008). We used detailed costing 
methods and considered the majority of resources paid for by the BC and Ontario Ministries of 
Health under comprehensive universal healthcare insurance plans. Furthermore, our study is the 
first to estimate phase-specific costs for all major cancers in BC and Ontario.
There were some limitations. We were not able to compare costs for emergency depart-
ment visits due to the lack of data in BC. Some cost estimations required making assumptions 
and extrapolations; in some cases, we were unable to account for all relevant costs. Although the 
number and type of individuals covered by the ODB and PharmaCare were quite similar, the 
drugs covered under the two plans may differ. Furthermore, interprovincial differences in chem-
otherapy and out-patient drug costs suggest hormone therapy (for example, for prostate cancer) 
may have been classified differently. We could not present costs by cancer stage because stage 
information was not available in either province for our analysis period. Previous research has 
found that costs are higher at advanced stages in which survival is generally short (Yabroff et al. 
2008). We did not examine the relative importance of age on average costs. Other work suggests 
that costs of cancer care are higher for younger patients (de Oliveira et al. 2013b). We estimated 
all healthcare costs incurred by patients, not net cancer costs (i.e., the difference between patients 
with and without cancer). Future work will use a matched case–control methodology (Brown et 
al. 1995, 2002; Taplin et al. 1995) to estimate net costs across phases of care.
Conclusion
Cancer exerts an enormous health and economic burden, which will likely rise in coming 
decades in Canada. Our findings highlight important cost differences between phases of 
care, cancer sites and resources within and between provinces. Comparative cost studies 
present many challenges but enable analyses within and between countries, and can produce 
comparable estimates for research, policy and decision-making.
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